



## **Synta to Host Investigator Panel Session on New Clinical Opportunities for Hsp90 Inhibition in Oncology**

March 21, 2011

*"The Future of NSCLC Therapy and the Re-emergence of Hsp90 Inhibition" to be webcast live on March 25 at 12:00 p.m. ET*

LEXINGTON, Mass., Mar 21, 2011 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will host a panel discussion on Friday, March 25, 2011 from 12:00 p.m. to 1:30 p.m. (ET) in New York.

The program, titled "The Future of NSCLC Therapy and the Re-emergence of Hsp90 Inhibition", will feature expert presentations on the landscape of Hsp90 inhibition, current treatment opportunities for NSCLC and a review of recent published data for ganetespib, Synta's lead Hsp90 inhibitor. The event will also include a panel discussion and question and answer session.

A live audio webcast and replay of the program will be available on the "Investors" section of the Company's website, [www.syntapharma.com](http://www.syntapharma.com).

Attendance at the event is by invitation only. Members of the professional investment community interested in attending may contact Aurora Krause at 781-541-7125 or [akrause@syntapharma.com](mailto:akrause@syntapharma.com).

### **About Ganetespib**

Ganetespib (formerly STA-9090) is a potent, synthetic, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins, and is recognized as a key facilitator of cancer cell growth and survival. In preclinical experiments, ganetespib has shown activity in multiple tumor models both as a single agent and in combination with certain widely used cancer agents. Ganetespib is currently being evaluated in a broad range of cancer clinical trials has shown clinical activity in patients who have progressed following treatment with multiple other therapies, and has been well tolerated to date with no evidence of severe liver or common ocular toxicities seen with other Hsp90 inhibitors. The most common adverse event seen to date has been diarrhea, which has been manageable with standard supportive care. Information on clinical trials with ganetespib can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

### **About Synta Pharmaceuticals**

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and

discovery capabilities. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

SOURCE: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.  
Rob Kloppenburg, 781-541-7125